Slammed 25% Ryvu Therapeutics S.A. (WSE:RVU) Screens Well Here But There Might Be A Catch
Jan 22
Have your own idea? Try our Stock Screener
Polish (WIG) Clinical Research and Equipment Industry Analysis
UpdatedJan 30, 2025
DataAggregated Company Financials
Companies5
- 7D1.2%
- 3M-21.7%
- 1Y-29.1%
- YTDn/a
The Clinical Research and Equipment industry is up 2.6% in the last week, with Ryvu Therapeutics up 3.0%. In the same time, Medicofarma Biotech was down 19%. In the past year, the industry is down 29%. As for the next few years, earnings are expected to grow by 7.2% per annum.
Industry Valuation and Performance
Has the Polish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 31 Jan 2025 | zł1.8b | zł427.0m | -zł65,964,174.00 | 16.1x | -27.1x | 4.2x |
| Sun, 29 Dec 2024 | zł2.0b | zł427.0m | -zł65,964,174.00 | 16.5x | -29.9x | 4.6x |
| Tue, 26 Nov 2024 | zł2.2b | zł427.0m | -zł66,551,174.00 | 18.2x | -33.3x | 5.2x |
| Thu, 24 Oct 2024 | zł2.3b | zł413.2m | -zł64,500,689.00 | 21.9x | -35.9x | 5.6x |
| Sat, 21 Sep 2024 | zł2.5b | zł421.4m | -zł39,488,869.00 | 17.7x | -62.3x | 5.8x |
| Mon, 19 Aug 2024 | zł2.4b | zł413.4m | -zł37,576,869.00 | 16.9x | -63.7x | 5.8x |
| Wed, 17 Jul 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 19.1x | -76.5x | 5.9x |
| Fri, 14 Jun 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 17.7x | -77.9x | 6x |
| Sun, 12 May 2024 | zł2.5b | zł421.0m | -zł26,364,957.00 | 17.9x | -94.4x | 5.9x |
| Tue, 09 Apr 2024 | zł2.6b | zł421.0m | -zł26,364,957.00 | 17.5x | -97.1x | 6.1x |
| Thu, 07 Mar 2024 | zł2.5b | zł495.9m | -zł52,637,957.00 | 44.9x | -48x | 5.1x |
| Sat, 03 Feb 2024 | zł2.5b | zł495.2m | -zł50,454,191.00 | 44.4x | -49.1x | 5x |
| Mon, 01 Jan 2024 | zł2.5b | zł495.2m | -zł50,454,191.00 | 44.1x | -49.1x | 5x |
| Wed, 29 Nov 2023 | zł2.6b | zł484.4m | -zł46,593,727.00 | 51.1x | -55.3x | 5.3x |
| Fri, 27 Oct 2023 | zł2.7b | zł512.0m | -zł37,354,934.00 | 33.2x | -73.5x | 5.4x |
| Sun, 24 Sep 2023 | zł2.8b | zł515.2m | -zł42,853,934.00 | 40.3x | -65.6x | 5.5x |
| Tue, 22 Aug 2023 | zł2.7b | zł507.8m | -zł51,598,105.00 | 44.5x | -53.3x | 5.4x |
| Thu, 20 Jul 2023 | zł2.8b | zł512.4m | -zł61,559,268.00 | 45.5x | -45.9x | 5.5x |
| Sat, 17 Jun 2023 | zł2.9b | zł512.4m | -zł61,559,268.00 | 45.7x | -46.4x | 5.6x |
| Mon, 15 May 2023 | zł2.8b | zł505.4m | -zł64,921,034.00 | 71.4x | -43.8x | 5.6x |
| Wed, 12 Apr 2023 | zł2.8b | zł505.4m | -zł64,921,034.00 | 68.5x | -42.7x | 5.5x |
| Fri, 10 Mar 2023 | zł3.2b | zł473.8m | -zł77,860,781.00 | 81x | -40.9x | 6.7x |
| Sun, 05 Feb 2023 | zł2.9b | zł483.0m | -zł79,277,613.00 | 60.7x | -37.2x | 6.1x |
| Tue, 03 Jan 2023 | zł2.8b | zł470.4m | -zł90,293,852.00 | 58.4x | -31.5x | 6.1x |
| Thu, 01 Dec 2022 | zł2.5b | zł473.2m | -zł84,720,511.00 | 34.3x | -30x | 5.4x |
| Sat, 29 Oct 2022 | zł2.3b | zł445.7m | -zł96,033,392.00 | 61.1x | -24.3x | 5.2x |
| Mon, 26 Sep 2022 | zł2.2b | zł443.7m | -zł83,357,892.00 | 62.1x | -26.8x | 5x |
| Wed, 24 Aug 2022 | zł2.2b | zł409.8m | -zł84,484,453.00 | 63.8x | -26.4x | 5.4x |
| Fri, 22 Jul 2022 | zł2.0b | zł417.3m | -zł76,832,012.00 | 54.1x | -26.6x | 4.9x |
| Sun, 19 Jun 2022 | zł1.7b | zł417.3m | -zł76,832,012.00 | 46.2x | -21.7x | 4x |
| Tue, 17 May 2022 | zł2.0b | zł383.3m | -zł65,630,938.00 | 50.5x | -31.1x | 5.3x |
| Thu, 14 Apr 2022 | zł2.3b | zł383.1m | -zł63,046,404.00 | 50.7x | -36.7x | 6x |
| Sat, 12 Mar 2022 | zł2.2b | zł316.7m | -zł60,433,049.00 | 56.7x | -36.7x | 7x |
| Mon, 07 Feb 2022 | zł2.5b | zł310.5m | -zł60,441,559.00 | 63.1x | -40.9x | 8x |
Price to Earnings Ratio
-40.9x
Current Industry PE
- Investors are pessimistic on the Polish Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.6x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 11% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Polish Clinical Research and Equipment compare with similar industries?
| PL Market | 1.03% | |
| Healthcare | -0.53% | |
| Life Sciences | 1.21% | |
| Clinical Research and Equipment | 1.21% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NNG NanoGroup | zł3.15 | 0.6% +zł562.5k | 240.9% | PS43881.7x |